Jean Cui

1.4k citations

18 papers · 1.0k indexed · h-index 10

Impact in

Oncology top 10%
- Lung Cancer Research Studies
Hepatology top 10%
- Liver physiology and pathology

Papers in ⓘ

Oncology 13
- Colorectal Cancer Treatments and Studies 4
- HER2/EGFR in Cancer Research 3
- Lung Cancer Research Studies 3
Hepatology 3
- Liver physiology and pathology 3

Co-authors: Sai‐Hong Ignatius Ou (4 shared papers)Mari Mino–Kenudson (1 shared paper)A. John Iafrate (1 shared paper)Cynthia Huang Bartlett (1 shared paper)James Cheng‐Chung Wei (3 shared papers)Cho Tang (3 shared papers)Asaad Nematalla (3 shared papers)Yong Zhou (3 shared papers)
Journals: Cancer Research (3 papers)Scientific Reports (1 paper)Organic Letters (1 paper)Bioorganic & Medicinal Chemistry Letters (1 paper)The Oncologist (1 paper)
Partner nations: United States Italy China

In The Last Decade

Jean Cui

18 papers receiving 1.0k citations

Peers

Countries citing papers authored by Jean Cui

Since Specialization

Citations

This map shows the geographic impact of Jean Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Cui more than expected).

Fields of papers citing papers by Jean Cui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Cui. The network helps show where Jean Cui may publish in the future.

Co-authors

The 25 scholars most cited alongside Jean Cui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jean Cui Line = papers co-authored together Jean Cui links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase Journal of Medicinal Chemistry ·Li Sun, Chris Liang, Sheri Shirazian, Yong Zhou, Todd Miller, Jean Cui, Juri Y. Fukuda, Ji-Yu Chu, Asaad Nematalla, Xueyan Wang, Hui Chen, Anand Sistla, Tony C. Luu, Flora Tang, James Cheng‐Chung Wei, Cho Tang	2003	423
2	Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology The Oncologist ·Sai‐Hong Ignatius Ou, Cynthia Huang Bartlett, Mari Mino–Kenudson, Jean Cui, A. John Iafrate	2012	160
3	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib Lung Cancer ·Sai‐Hong Ignatius Ou, Jean Cui, Alexa B. Schrock, Michael E. Goldberg, Viola W. Zhu, Lee A. Albacker, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali	2017	125
4	Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a Proceedings of the National Academy of Sciences ·Nikolaus Schiering, Stefan Knapp, M. Marconi, Maria M. Flocco, Jean Cui, Rita Perego, Luisa Rusconi, Cinzia Cristiani	2003	118
5	Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors Biochemistry ·Sergei Timofeevski, Michele McTigue, Kevin Ryan, Jean Cui, Helen Y. Zou, Jeff Zhu, Fannie Chau, Gordon Alton, Shannon Karlicek, James G. Christensen, Brion W. Murray	2009	75
6	Synthesis of Aryl Ethers via a Sulfonyl Transfer Reaction Organic Letters ·Neal W. Sach, Daniel T. Richter, Stephan J. Cripps, Michelle Tran‐Dubé, Huichun Zhu, Buwen Huang, Jean Cui, Scott C. Sutton	2012	28
7	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review JTO Clinical and Research Reports ·Viola W. Zhu, Misako Nagasaka, Russell W. Madison, Alexa B. Schrock, Jean Cui, Sai‐Hong Ignatius Ou	2020	27
8	Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185erbB) tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Li Sun, Jean Cui, Congxin Liang, Yong Zhou, Asaad Nematalla, Xueyan Wang, Hui Chen, Cho Tang, James Cheng‐Chung Wei	2002	20
9	Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells Scientific Reports ·Diana Cervantes-Madrid, Joanna Szydzik, Dan E. Lind, Marcus Borenäs, Mats Bemark, Jean Cui, Ruth H. Palmer, Bengt Hallberg	2019	16
10	Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma Annals of Translational Medicine ·Imane Chaib, Xueting Cai, David Lligé, Mariacarmela Santarpía, Eloísa Jantus‐Lewintre, Martyna Filipska, Carlos Pedraz, Jean Cui, Jie Yang, Miao Jing, Rongwei Sun, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Jordi Codony‐Servat, Niki Karachaliou, Andrés Aguilar, Rafael Rosell, Peng Cao	2019	14
11	Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer Clinical Lung Cancer ·Lihong Zhang, Xia Yang, Zongjuan Ming, Jie Shi, Xin Lv, Wei Li, Bo Yuan, Yang Chen, Boxuan Liu, Kai Qin, Jiamin Liu, Qingbo Wei, Dejian Gu, Rongrong Chen, Mingming Yuan, Jean Cui, Sai‐Hong Ignatius Ou, Shuanying Yang	2021	8
12	Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases Expert Opinion on Therapeutic Patents ·Jean Cui	2006	7
13	ChemInform Abstract: Rational Design of 4,5‐Disubstituted‐5,7‐dihydro‐pyrrolo[2,3‐d]pyrimidin‐6‐ones as a Novel Class of Inhibitors of Epidermal Growth Factor Receptor (EGF‐R) and Her2(p185^erbB) Tyrosine Kinases. ChemInform ·Li Sun, Jean Cui, Congxin Liang, Yong Zhou, Asaad Nematalla, Xueyan Wang, Hui Chen, Cho Tang, James Cheng‐Chung Wei	2002	1
14	Osimertinib and Dihydroartemisinin: A Novel Drug Combination Targeting Head and Neck Squamous Cell Carcinoma SSRN Electronic Journal ·Imane Chaib, Xueting Cai, David Lligé, Mariacarmela Santarpía, Eloísa Jantus‐Lewintre, Martyna Filipska, Carlos Pedraz, Jean Cui, Jie Yang, Miao Jing, Rongwei Sun, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Jordi Codony Servat, Niki Karachaliou, Rafael Rosell, Peng Cao	2019	1
15	Abstract 2327: Structural and kinetic characterization of crizotinib with wild-type and mutant anaplastic lymphoma kinase Cancer Research ·Michele McTigue, Sergei Timofeevski, Wei Liu, Ya‐Li Deng, Tami Marrone, Jean Cui, Alexei Brooun	2011	1
16	Accidental and Intentional Overdose of Imatinib: a Report of Outcome and Side Effect of 46 Cases. Blood ·François Guilhot, Alan K. Hatfield, Frédéric Millot, Lydia Roy, Mathiéu Molimard, Jean Cui	2009	1
17	Abstract 3168: Overcoming acquired drug resistance by TPX-0005, an ALK, ROS1 and pan-TRK inhibitor Cancer Research ·Wei Deng, David C.S. Huang, Dayong Zhai, Evan Rogers, Jean Cui	2017	1
18	Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation Cancer Research ·Satoshi Yoda, Leila Dardaei, Kylie Prutisto-Chang, Jean Cui, Alice T. Shaw, Aaron N. Hata	2018	1

About Jean Cui

Jean Cui is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Molecular Biology and Organic Chemistry, having authored 18 papers that have together received 1.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Cancer therapeutics and mechanisms (5 papers), Colorectal Cancer Treatments and Studies (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), HER2/EGFR in Cancer Research (3 papers), Liver physiology and pathology (3 papers), Lung Cancer Research Studies (3 papers) and Quinazolinone synthesis and applications (2 papers). The work is most often cited by research in Oncology (407 citations), Hepatology (104 citations), Pulmonary and Respiratory Medicine (427 citations), Cancer Research (141 citations) and Organic Chemistry (231 citations). Jean Cui has collaborated with scholars based in United States, Italy and China. Frequent co-authors include Sai‐Hong Ignatius Ou, Mari Mino–Kenudson, A. John Iafrate, Cynthia Huang Bartlett, James Cheng‐Chung Wei, Cho Tang, Asaad Nematalla, Yong Zhou, Hui Chen and Xueyan Wang. Their work appears in journals such as Cancer Research, Scientific Reports, Organic Letters, Bioorganic & Medicinal Chemistry Letters and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact